Updated on 20 September 2026
Strategic Partnership for Diagnostics and Global Expansion
Board Director CFO at IMMUNOSENS Co., Ltd.
Osaka, Japan
About
IMMUNOSENS is an Osaka University spin-off developing a compact and quantitative point-of-care testing platform based on our proprietary GLEIA technology.
Our system enables rapid quantitative measurement using a very small sample volume and is designed for use not only in hospitals and clinics, but also in home healthcare and wellness applications.
We are seeking strategic partners in the following areas:
-
Business development and commercialization
-
Collaboration in diagnostics, healthcare, and chronic disease management
-
Joint product and technology development
-
Distribution and market access in Japan and overseas
-
Expansion into Europe and other global markets
-
Potential investment and strategic capital partnerships
We are particularly interested in discussions with pharmaceutical companies, medical device and diagnostic companies, healthcare providers, distributors, and investors who see potential in decentralized and home-based testing.
We would be pleased to explore opportunities for collaboration and long-term partnership.
Organisation
Similar opportunities
Partnership
Japan Strategic Partnership for AI, Digital Health & Wearable Technology
Thiruvikkiraman Pandurangan
Founder/CEO at Neurolonic UG
Berlin, Germany
Investment
Strategic Investment in AI, Digital Health & Human Wellbeing
- Expansion
- Healthcare
- Electronics
- Growth and Establishment
- ICT Industry and Services
Thiruvikkiraman Pandurangan
Founder/CEO at Neurolonic UG
Berlin, Germany
Partnership
AT Market Development Partnership: Japan ⇄ Europe
Tomofumi Fukamiya
CEO at The Elements, Inc.
Tokyo, Japan